Gary Nachman
Stock Analyst at Raymond James
(3.00)
# 1,277
Out of 5,165 analysts
97
Total ratings
58.9%
Success rate
5.49%
Average return
Main Sectors:
Stocks Rated by Gary Nachman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IONS Ionis Pharmaceuticals | Reiterates: Strong Buy | $85 → $89 | $72.33 | +23.05% | 4 | Oct 30, 2025 | |
| BLCO Bausch + Lomb | Reiterates: Outperform | $18 → $19 | $16.71 | +13.70% | 2 | Oct 30, 2025 | |
| LENZ LENZ Therapeutics | Reiterates: Outperform | $40 → $50 | $12.50 | +300.00% | 3 | Oct 20, 2025 | |
| ABBV AbbVie | Reiterates: Outperform | $236 → $250 | $219.76 | +13.76% | 17 | Oct 17, 2025 | |
| AMGN Amgen | Assumes: Market Perform | n/a | $361.13 | - | 2 | Sep 3, 2025 | |
| VERU Veru Inc. | Maintains: Outperform | $30 → $20 | $2.41 | +729.88% | 2 | Aug 13, 2025 | |
| SDGR Schrödinger | Maintains: Outperform | $25 → $28 | $12.29 | +127.83% | 5 | Nov 13, 2024 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Outperform | $275 → $298 | $320.42 | -7.00% | 7 | Nov 1, 2024 | |
| ACHV Achieve Life Sciences | Initiates: Strong Buy | $20 | $4.25 | +370.59% | 1 | Sep 27, 2024 | |
| PCRX Pacira BioSciences | Maintains: Outperform | $41 → $37 | $21.94 | +68.64% | 13 | Jul 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Strong Buy | $30 | $40.71 | -26.31% | 5 | Mar 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $7 | $4.11 | +70.32% | 1 | Mar 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | n/a | $181.37 | - | 11 | Sep 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $5 → $4 | $12.43 | -67.82% | 5 | Mar 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $35 → $30 | $10.85 | +176.50% | 4 | Mar 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 → $32 | $3.55 | +801.41% | 1 | Feb 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $16 → $14 | $13.80 | +1.45% | 2 | Feb 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $11 → $10 | $30.09 | -66.77% | 1 | Nov 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 → $30 | $26.38 | +13.72% | 2 | Nov 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $810 → $750 | $4.56 | +16,347.37% | 2 | Aug 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $15 → $8 | $5.18 | +54.44% | 2 | Aug 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $20 → $21 | $19.51 | +7.64% | 5 | May 11, 2020 |
Ionis Pharmaceuticals
Oct 30, 2025
Reiterates: Strong Buy
Price Target: $85 → $89
Current: $72.33
Upside: +23.05%
Bausch + Lomb
Oct 30, 2025
Reiterates: Outperform
Price Target: $18 → $19
Current: $16.71
Upside: +13.70%
LENZ Therapeutics
Oct 20, 2025
Reiterates: Outperform
Price Target: $40 → $50
Current: $12.50
Upside: +300.00%
AbbVie
Oct 17, 2025
Reiterates: Outperform
Price Target: $236 → $250
Current: $219.76
Upside: +13.76%
Amgen
Sep 3, 2025
Assumes: Market Perform
Price Target: n/a
Current: $361.13
Upside: -
Veru Inc.
Aug 13, 2025
Maintains: Outperform
Price Target: $30 → $20
Current: $2.41
Upside: +729.88%
Schrödinger
Nov 13, 2024
Maintains: Outperform
Price Target: $25 → $28
Current: $12.29
Upside: +127.83%
Alnylam Pharmaceuticals
Nov 1, 2024
Maintains: Outperform
Price Target: $275 → $298
Current: $320.42
Upside: -7.00%
Achieve Life Sciences
Sep 27, 2024
Initiates: Strong Buy
Price Target: $20
Current: $4.25
Upside: +370.59%
Pacira BioSciences
Jul 31, 2024
Maintains: Outperform
Price Target: $41 → $37
Current: $21.94
Upside: +68.64%
Mar 28, 2024
Initiates: Strong Buy
Price Target: $30
Current: $40.71
Upside: -26.31%
Mar 28, 2024
Initiates: Outperform
Price Target: $7
Current: $4.11
Upside: +70.32%
Sep 29, 2023
Initiates: Market Perform
Price Target: n/a
Current: $181.37
Upside: -
Mar 3, 2023
Maintains: Market Perform
Price Target: $5 → $4
Current: $12.43
Upside: -67.82%
Mar 1, 2023
Maintains: Outperform
Price Target: $35 → $30
Current: $10.85
Upside: +176.50%
Feb 22, 2023
Maintains: Outperform
Price Target: $40 → $32
Current: $3.55
Upside: +801.41%
Feb 17, 2023
Downgrades: Market Perform
Price Target: $16 → $14
Current: $13.80
Upside: +1.45%
Nov 7, 2022
Maintains: Market Perform
Price Target: $11 → $10
Current: $30.09
Upside: -66.77%
Nov 4, 2022
Maintains: Outperform
Price Target: $40 → $30
Current: $26.38
Upside: +13.72%
Aug 11, 2022
Maintains: Outperform
Price Target: $810 → $750
Current: $4.56
Upside: +16,347.37%
Aug 10, 2022
Maintains: Market Perform
Price Target: $15 → $8
Current: $5.18
Upside: +54.44%
May 11, 2020
Maintains: Market Perform
Price Target: $20 → $21
Current: $19.51
Upside: +7.64%